# High CDCP1 Expression Reflects Immune and Stromal Remodeling and Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma

## TL;DR

This study finds that high CDCP1 levels in pancreatic cancer are linked to immune evasion, stromal changes, and cancer-promoting signals, suggesting CDCP1 could be a useful biomarker or treatment target.

## Contribution

The study identifies CDCP1 as a marker of immune-excluded tumor environments and active oncogenic pathways in pancreatic cancer.

## Key findings

- High CDCP1 expression correlates with reduced CD8+ T cells, adipocytes, and fibroblasts in the tumor microenvironment.
- CDCP1 is associated with increased genomic instability and enrichment of protumorigenic pathways like glycolysis and TGF-β signaling.
- CDCP1 defines a distinct pancreatic cancer subtype marked by immune evasion and stromal depletion.

## Abstract

CUB domain-containing protein 1 (CDCP1) is implicated in pancreatic ductal adenocarcinoma (PDAC) prognosis, but its relationship to the tumor microenvironment (TME) and oncogenic signaling remains incompletely defined. We hypothesized that CDCP1 expression is associated with hallmark cancer signaling pathways and transcriptionally inferred TME remodeling in PDAC.

We analyzed transcriptomic and clinical data from 214 PDAC cases (The Cancer Genome Atlas (TCGA), n = 145; GSE62452, n = 69). Patients were stratified into high CDCP1 and low CDCP1 groups based on the top tertile of expression. Immune and stromal components of the TME were quantified using the xCell algorithm. Gene Set Enrichment Analysis (GSEA) with Hallmark gene sets was used for pathway enrichment.

High CDCP1 expression was significantly associated with reduced infiltration of CD8+ T cells, adipocytes, and fibroblasts, suggesting an immune-excluded and stromally depleted TME. It also correlated with increased homologous recombination deficiency scores, mutation burden, and single-nucleotide variants. CDCP1 expression correlated with CDKN2A mutation but was only weakly associated with KRAS, TP53, and SMAD4 alterations. GSEA showed consistent enrichment of proliferative (E2F, MYC, G2M, p53) and protumorigenic (transforming growth factor-β, hypoxia, glycolysis) pathways in high CDCP1 tumors across both datasets.

CDCP1 defines a transcriptionally distinct PDAC subtype characterized by immune evasion, stromal depletion, and genomic instability. These findings highlight CDCP1 as a potential therapeutic target and biomarker reflecting interplay between oncogenic signaling and the TME.